Platelet-Rich Plasma for Peyronie's Disease
Treatment of Peyronie's Disease With Platelet-Rich Plasma: A Randomized, Double-blind, Placebo-controlled Clinical Trial
Herlev Hospital
84 participants
Sep 20, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this clinical trial is to evaluate the effects of Platelet-Rich Plasma (PRP) intralesional injections in men affected by Peyronie's disease (PD) in the fibrotic phase.
Eligibility
Inclusion Criteria5
- years or older
- Be able to provide written informed consent
- Diagnosis of PD without active pain and without progressive curvature over the past 3 months (fibrotic phase).
- Penile curvature of 30-95 degrees
- Clearly palpable penile plaque
Exclusion Criteria8
- Erectile Dysfunction unresponsive to on-demand PDE5 inhibitors
- Hourglass malformation
- Severely calcified plaques where injection is considered unfeasible
- Intrapenile plaque
- History of priapism.
- History of penile fracture.
- Previous treatment for PD with injections and/or surgery.
- Antithrombotic therapy associated with a high risk of bleeding
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
6 mL PRP intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.
6 mL saline solution intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07117955